Phosphoproteomic analysis conducted on BRAF-mutant melanoma cell lines showed, after treatment with vemurafenib or after BRAF gene silencing, an increased expression of fibronectin, only in PTEN-loss contexts. The gene discussed is PTEN; the disease is melanoma.